Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cabaletta Bio Inc (CABA)

Cabaletta Bio Inc (CABA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 134,412
  • Shares Outstanding, K 48,877
  • Annual Sales, $ 0 K
  • Annual Income, $ -67,680 K
  • EBIT $ -115 M
  • EBITDA $ -114 M
  • 60-Month Beta 2.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.76

Options Overview Details

View History
  • Implied Volatility 209.50% ( +38.96%)
  • Historical Volatility 173.76%
  • IV Percentile 87%
  • IV Rank 18.66%
  • IV High 861.91% on 08/12/24
  • IV Low 59.81% on 07/31/24
  • Put/Call Vol Ratio 0.58
  • Today's Volume 1,323
  • Volume Avg (30-Day) 3,933
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 33,712
  • Open Int (30-Day) 21,751

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.66
  • Number of Estimates 5
  • High Estimate -0.63
  • Low Estimate -0.70
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -43.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.76 +30.11%
on 11/21/24
5.46 -58.06%
on 12/02/24
-0.41 (-15.19%)
since 11/18/24
3-Month
1.76 +30.11%
on 11/21/24
5.46 -58.06%
on 12/02/24
-2.19 (-48.88%)
since 09/18/24
52-Week
1.76 +30.11%
on 11/21/24
26.35 -91.31%
on 02/08/24
-18.57 (-89.02%)
since 12/18/23

Most Recent Stories

More News
Cabaletta Bio to Participate in Upcoming Investor Conferences in December

CABA : 2.29 (-16.73%)
2 Penny Stocks That Wall Street Predicts Will Soar 306% to 1,183% in 2025

Both penny stocks are a 'strong buy' on Wall Street.

CABA : 2.29 (-16.73%)
$SPX : 5,872.16 (-2.95%)
NTLA : 12.02 (-8.45%)
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

CABA : 2.29 (-16.73%)
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

CABA : 2.29 (-16.73%)
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

CABA : 2.29 (-16.73%)
Why Shares of Cabaletta Bio Are Up Tuesday

The biotech stock rose after an analyst upgrade.

CABA : 2.29 (-16.73%)
Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and...

CABA : 2.29 (-16.73%)
Cabaletta Bio Presents Updated Interim DesCAARTesâ„¢ Trial Phase 1 Data at the ASGCT 25th Annual Meeting

PHILADELPHIA, May 18, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and...

CABA : 2.29 (-16.73%)
Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update

– DesCAARTes™ trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be presented at upcoming...

CABA : 2.29 (-16.73%)
Cabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May

PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and...

CABA : 2.29 (-16.73%)

Business Summary

Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are...

See More

Key Turning Points

3rd Resistance Point 3.23
2nd Resistance Point 3.02
1st Resistance Point 2.65
Last Price 2.29
1st Support Level 2.07
2nd Support Level 1.86
3rd Support Level 1.49

See More

52-Week High 26.35
Fibonacci 61.8% 16.96
Fibonacci 50% 14.06
Fibonacci 38.2% 11.15
Last Price 2.29
52-Week Low 1.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar